XML 80 R48.htm IDEA: XBRL DOCUMENT v3.20.4

Segments (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Information by Reportable Segment

Information by reportable segment was as follows:

			PGEN Therapeutics						ActoBio												Trans Ova						Human Biotherapeutics						All Other						Total
Goodwill
Balances at December 31, 2018			$	15,232					$	1,788											$	46,236					$	—					$	20,736					$	83,992
Reallocations from changes to reporting units			—						—												—						482						(482)						—
Impairments			—						—												(29,642)						—						(178)						(29,820)
Foreign currency translation adjustments			—						(53)												—						—						—						(53)
Balances at December 31, 2019			15,232						1,735												16,594						482						20,076						54,119
Foreign currency translation adjustments			—						244												—						—						—						244
Balances at December 31, 2020			$	15,232					$	1,979											$	16,594					$	482					$	20,076					$	54,363

			Year Ended December 31, 2020
			PGEN Therapeutics						ActoBio												Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	776					$	3,053											$	71,186					$	17,810					$	10,299					$	103,124
Intersegment revenues			5,006						(3)												340						—						281						5,624
Total segment revenues			$	5,782					$	3,050											$	71,526					$	17,810					$	10,580					$	108,748
Segment Adjusted EBITDA			$	(25,611)					$	(7,861)											$	2,624					$	(2,139)					$	4,274					$	(28,713)

			Year Ended December 31, 2019
			PGEN Therapeutics						ActoBio												Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	2,227					$	(364)											$	68,672					$	3,713					$	12,514					$	86,762
Intersegment revenues			11,341						498												1,361						—						1,270						14,470
Total segment revenues			$	13,568					$	134											$	70,033					$	3,713					$	13,784					$	101,232
Segment Adjusted EBITDA			$	(30,164)					$	(13,662)											$	(6,337)					$	(1,051)					$	(4,901)					$	(56,115)

			Year Ended December 31, 2018
			PGEN Therapeutics						ActoBio												Trans Ova						Human Biotherapeutics						All Other						Total
Revenues from external customers			$	29,021					$	6,684											$	75,178					$	—					$	30,213					$	141,096
Intersegment revenues			617						840												558						—						255						2,270
Total segment revenues			$	29,638					$	7,524											$	75,736					$	—					$	30,468					$	143,366
Segment Adjusted EBITDA			$	(32,832)					$	(12,797)											$	(5,730)					$	—					$	(10,708)					$	(62,067)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:

			Year Ended December 31,
			2020						2019						2018
Total segment revenues from reportable segments			$	98,168					$	87,448					$	112,898
Other revenues, including from other operating segments			10,634						17,964						40,841
Elimination of intersegment revenues			(5,624)						(14,690)						(2,561)
Total consolidated revenues			$	103,178					$	90,722					$	151,178

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

			Year Ended December 31,
			2020						2019						2018
Segment Adjusted EBITDA for reportable segments			$	(32,987)					$	(51,214)					$	(51,359)
All Other Segment Adjusted EBITDA			4,274						(4,901)						(10,708)
Remove cash paid for capital expenditures and investments in affiliates			6,970						12,512						15,276
Add recognition of previously deferred revenue associated with upfront and milestone payments			25,005						14,721						33,204
Other expenses:
Interest expense			(18,400)						(17,666)						(8,473)
Depreciation and amortization			(15,042)						(16,142)						(20,612)
Impairment losses			(920)						(30,810)						—
Reacquisition of in-process research and development			—						—						(236,748)
Loss on settlement agreement			(11,436)						—						—
Stock-based compensation expense			(19,746)						(15,098)						(30,554)
Adjustment related to accrued bonuses paid in equity awards			2,833						—						—
Equity in net loss of affiliates			(1,138)						(2,416)						(8,986)
Other			11						67						—
Unallocated corporate costs			(37,566)						(46,011)						(74,609)
Eliminations			(5,713)						(14,306)						(2,343)
Consolidated net loss from continuing operations before income taxes			$	(103,855)					$	(171,264)					$	(395,912)

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration